Side-by-side comparison of AI visibility scores, market position, and capabilities
Sports betting analytics platform with statistical models and matchup analysis; player props, injury news, and betting line tracking for recreational bettors in the expanding US sports wagering market.
Trendex is a sports betting and fantasy sports analytics platform providing statistical modeling, injury news, matchup analysis, and data-driven betting insights for recreational and serious sports bettors across football, basketball, baseball, and soccer — delivering content through a mobile app and website in the rapidly expanding US sports betting market following the 2018 PASPA Supreme Court ruling that legalized sports betting nationwide. Founded in 2021 and headquartered in the United States, Trendex targets sports fans who want data-driven edge in their sports betting and daily fantasy sports (DFS) decisions.\n\nTrendex aggregates player statistics, team performance metrics, injury reports, weather conditions, betting lines from major sportsbooks, and historical matchup data into predictive models that surface betting edges and player prop value for daily fantasy contests. The platform provides projected stats, injury probability, betting line movement analysis, and community picks from expert analysts. The mobile experience is designed for in-game consumption — checking player stats and injury news during live games.\n\nIn 2025, Trendex operates in the sports analytics and betting media market alongside established players like The Action Network (Chernin Group), DraftKings Rotogrinders, RotoWire, and ESPN Bet Insider for sports betting information. The US sports betting market has grown dramatically since legalization — approximately 30 states have legalized sports wagering — creating large consumer demand for actionable betting information. Trendex competes for user attention against free tools embedded in sportsbook apps (DraftKings, FanDuel, BetMGM all provide analytics within their apps) and established sports media brands. The 2025 strategy focuses on growing its subscriber base, adding more AI-powered predictive features, and expanding into additional sports leagues and international markets.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.